<DOC>
	<DOCNO>NCT02955134</DOCNO>
	<brief_summary>The purpose study evaluate long-term efficacy Chinese medicine treatment chronic atrophic gastritis . It multi-center , randomize , placebo-controlled trial .</brief_summary>
	<brief_title>The Study Chinese Medicine Treatment Chronic Atrophic Gastritis</brief_title>
	<detailed_description>A prospective , double-blind , randomize , placebo-controlled , multi-center trial carry study.The sample size 468 patient ( 312 experimental group , 156 control group ) . The investigator screen patient inclusion accord inclusion exclusion criterion . All patient undergo carbon-13 label urea breath test , upper digestive endoscopy biopsy histological investigation . Patients infected H.pylori must receive H.pylori eradication therapy guidance Kyoto global consensus report H.pylori gastritis . Then assign experimental group control group allocation ratio 2:1 . Patients experimental group take traditional Chinese medicine prescription , control group take simulate granule prescription . Both two group symptomatic treatment . Treatment duration last 24 week . Investigators also follow another 24 week . Histological change use primary outcome index . Endoscopy finding , symptom assess . Serum level pepsinogen patient-reported outcome instrument also administer study . All biopsy specimen collect build biological specimen bank . Central blind histological assessment ( Histological diagnosis determine independently three experienced pathologist blind information patient . ) use insure accuracy consistency . Tele-medicine information management system establish help achieve follow-up interview . Random number generate SAS 9.4 software . The subject , caregiver , investigator outcomes assessor study blind .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Gastritis , Atrophic</mesh_term>
	<mesh_term>Hydrotalcite</mesh_term>
	<criteria>Inclusion criterion 1 . Patients diagnose chronic atrophic gastritis . 2 . Patients histological diagnosis atrophy ( reduction gland ) mild/moderate gradeï¼Œwith without mild/moderate intestinal metaplasia , without mild/moderate dysplasia . 3 . Aged 40 65 year old , male female . 4 . Patients agree participate clinical study inform consent . 5 . Local resident ensure regular treatment followup . 6 . Not take aspirin , warfarin anticoagulant without coagulation disorder . Exclusion criteria 1 . Autoimmune gastritis . 2 . The combined gastric duodenal ulcer , upper gastrointestinal bleeding . 3 . Dysplasia severe degree , suspicious gastric malignancy . 4 . Serious comorbidities heart , lung , liver , kidney blood system ( cardiac function grade II , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) great 1.5 time upper limit normal , creatinine ( Cr ) great upper limit normal ) lifethreatening illness . 5 . Psychiatric disorder history alcohol drug abuse . 6 . Pregnant lactating woman . 7 . Allergic trial drug . 8 . Patients judge inappropriate participate trial investigator . 9 . Patients enrol another clinical trial last two month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>central blind histological assessment</keyword>
	<keyword>traditional Chinese medicine intervention</keyword>
	<keyword>long-term follow-up study</keyword>
	<keyword>biological specimen bank</keyword>
</DOC>